Great West Life Assurance Co. Can decreased its position in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 681,690 shares of the medical research company’s stock after selling 14,417 shares during the period. Great West Life Assurance Co. Can owned 0.09% of Amgen worth $111,758,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock valued at $5,963,875,000 after buying an additional 4,144,154 shares during the last quarter. Norges Bank bought a new stake in shares of Amgen during the fourth quarter valued at about $1,016,913,000. Loomis Sayles & Co. L P raised its stake in shares of Amgen by 4.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 3,001,021 shares of the medical research company’s stock valued at $438,779,000 after buying an additional 133,918 shares during the period. Bank of Montreal Can raised its stake in shares of Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock valued at $465,543,000 after buying an additional 269,586 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of Amgen during the fourth quarter valued at about $275,209,000. Institutional investors own 78.80% of the company’s stock.
Amgen Inc. (AMGN) opened at 177.40 on Tuesday. The stock has a market cap of $130.46 billion, a price-to-earnings ratio of 16.85 and a beta of 1.35. The firm has a 50-day moving average price of $162.22 and a 200-day moving average price of $162.64. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.15. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The company had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the business posted $2.90 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. Equities research analysts expect that Amgen Inc. will post $12.47 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Great West Life Assurance Co. Can Has $111.76 Million Position in Amgen Inc. (AMGN)” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thestockobserver.com/2017/07/18/amgen-inc-amgn-stake-reduced-by-great-west-life-assurance-co-can-updated.html.
Several brokerages recently issued reports on AMGN. Jefferies Group LLC reaffirmed a “buy” rating and set a $195.00 price target on shares of Amgen in a report on Monday. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the stock a “hold” rating in a report on Friday. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research report on Friday. Morgan Stanley restated an “overweight” rating on shares of Amgen in a research report on Monday, July 10th. Finally, Mizuho reiterated a “buy” rating and set a $195.00 target price on shares of Amgen in a research report on Sunday, July 9th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and three have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $185.17.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.